BioNTech Secures 81.7% of CureVac Shares in Tender Offer
BioNTech has initiated an offer to exchange American Depositary Shares for CureVac shares, securing 81.7% of CureVac shares. Relevant documents have been filed with the U.S. SEC, and CureVac has submitted a recommendation statement. This information is based on a news brief created by Public Technologies using AI and originally published by BioNTech via GlobeNewswire on December 03, 2025.
BioNTech is proceeding with an offer to exchange American Depositary Shares (ADSs) for shares of CureVac. The offer has commenced, and relevant documents including an exchange offer prospectus and related materials have been filed with the U.S. Securities and Exchange Commission. CureVac has also submitted a recommendation statement regarding the offer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001142591-de) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
